Novartis Ag

Bristol-myers Squibb Compnay

Sloan-kettering Institute for Cancer Research

Novartis Vaccines & Diagnostics, Gmbh

James Clifford Sutton

Qian Zhao

Martin Sendzik

James R Manning

Lifeng Wan

Lawrence G Hamann

Keith Bruce Pfister

Tammy C Wang

Benjamin R Taft

Gang Liu

Cynthia Shafer

Yingzhi Bi

Michael David Shultz

Rejean Ruel

Julian Roy Levell

Jeffrey A Robl

Daniel J Poon

Jennifer X Qiao

Gregory S Bisacchi

Jiong Lan

Zhuoliang Chen

Allan S Wagman

Simon C Ng

Aregahegn Yifru

Hong Yang

David John Augeri

Weibo Wang

Savithri Ramurthy

William A Slusarchyk

James J Li

Shung C Wu

Paul Andrew Barsanti

Zulan Pi

Patrick Y S Lam

Xiaodong Lin

Mika Lindvall

Mark C Manfredi

Cheng Hu

Timur Gungor

Uwe D Treuner

Robert Zahler

R Michael Lawrence

Yan Shi

David R Kronenthal

David R Magnin

Chongqing Sun

Guohua Zhao

Troy Douglas Smith

Fan Yang

Mark G Palermo

Rama Jain

Dennis Christofer Koester

Abran Q Costales

Young Shin Cho

Marion Wiesmann

Thomas Raymond Caferro

Alexandra A Nirschl

Yaping Wang

Vanessa Marx

Ligaya Simpkins

Nicholas M Valiante

Carl Thibeault

Alexandre L'Heureux

Yue Pan

Chong-qing Sun

Robert F Keyes

Jeff Xianming Jin

Elizabeth J Mieuli

Victoria Sung

Anu Sharma

Alexandra Holubec

Yan-Ting Huang

Robert Kucejko

Liana M Klivansky

William Lenahan

Susan Kaufman

Bakary-Barry Toure

Hannguang J Chao

Mark Gabriel Palermo

Carl Thibault

Zhongping Shi

Daniel L Cheney

Dylan L Daniel

Michael E Randazzo

Mark D Schwinden

Yan Zou

Huangshu Lei

Francois Lenoir

Zhongmin Xu

Mark S Kirby

Feng Xu

Steven M Seiler

Ashish Khanna

Uwe Treuner

Johanna Joyce

Nicholas Valiante

Mika K Lindvall

William P Lenahan

The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.

Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections

The present invention provides a compound of Formula (I) including pharmaceutically acceptable salts thereof: (I) and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions to treat viral infections. 

Tricyclic compounds useful to treat orthomyxovirus infections

The present invention provides a compound of Formula (I) including pharmaceutically acceptable salts thereof: and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions to treat viral infections.

The present invention provides a compound of formula I; 

CSF-1R inhibitors for treatment of brain tumors

The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R, R, Rand R-Rare herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH

The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R-Rare defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer. 

The present invention provides a compound of formula (I): 

Heteroaryl compounds and their uses

Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided is a method of treating a disease or condition mediated by CDK9.

The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Yreceptor which can be used as medicaments.

N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions

Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.

CSF-1R inhibitors, compositions, and methods of use

Growing community of inventors

Pleasanton, CA, United States of America

James Clifford Sutton